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Available online 5 March 2008Activity and stability of the proto-oncogene c-Myb are regulated by post-translational modiﬁcations, though
the molecular mechanisms underlying such control are only partially understood. Here we describe the
functional interaction of c-Myb with Pin1, an isomerase that binds to phosphorylated Ser/Thr-Pro motifs. We
found that co-expression of c-Myb and Pin1 led to a net increase of c-Myb transactivation activity, both on
reporter constructs as well as on an endogenous target gene. DNA-binding studies revealed that Pin1 did not
increase the association of c-Myb with its response element in DNA. The increase of c-Myb transactivation
activity was strictly dependent on the presence of an active catalytic center in Pin1. We provide evidence that
c-Myb and Pin1 physically interacted, both upon ectopic expression of the proteins in HEK-293 cells as well as
in the more physiological setting of HL60 cells, where c-Myb and Pin1 are resident proteins. By point mutating
each individual Ser/Thr-Pro motif in c-Myb as well as by using deletion mutants we show that S528 in the
EVES-motif was the docking site for Pin1. Mass spectrometry conﬁrmed that S528 is phosphorylated in vivo.
Finally, functional studies showed that mutation of S528 to alanine almost abolished the increase of
transactivation activity by Pin1. This study reveals a new paradigm by which phosphorylation controls c-Myb
function.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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Transcription1. Introduction
Transduction of external stimuli to the interior of the cell ismediated
by networks of signaling pathways that impinge on the cell metabolism
and the cell division cycle. Post-translational modiﬁcation of signaling
elements plays a key role in the ampliﬁcation of internalized signals.
Phosphorylation is the most widespread reversible post-translational
modiﬁcation of proteins and results in rapid modulation of activity,
conformation, localization and interaction of proteins.
The myb transcriptional regulators comprise a family of related
nuclear DNA-binding proteins that display high homology in their
DNA-binding domains. Members of this family have been identiﬁed in
mammals, avians, insects, yeast, slime mold and plants [1]. C-myb is
the progenitor of the v-myb oncogene that was ﬁrst identiﬁed in avian
AMV and E26 retroviruses and was shown to cause avian myelomo-
nocytic leukemias [2,3]. Deregulated c-myb expression was later
linked to the development of myeloid leukemia in mice [4] and shown
to be predictive of poor prognosis in human colorectal cancer [5]. As
observed in avian leukemias, a truncated and hyperactive c-Myb
protein was detected in a CML patient undergoing T cell blast crisis,41 44 635 3484.
16, I-20138 Milano, Italy.
l rights reserved.thus documenting the presence of deleted c-Myb isoforms in humans
[6].
All Myb family members display a DNA-binding domain at the N-
terminus, which consists of three imperfect tandem repeats. A cluster
of tryptophan residues in the three repeats is believed to form a
hydrophobic core in the protein that generates the helix-turn-helix
structure of the DNA-binding domain [7]. This is followed by an acidic
transactivation region in the central part of the protein and a putative
negative regulatory domain at the C-terminus [8].
The product of the c-myb gene is selectively expressed in immature
myeloid, lymphoid anderythroid cells [9,10] aswell as in the colon [11].
In addition to tissue speciﬁcity, c-myb displays a temporal pattern of
expression in the embryo [10] and in the adult organism [12]. High
levels of c-myb expression were reported at sites of deﬁnitive
hematopoiesis [10], which is also known as “second wave” of hema-
topoiesis in mammalian embryogenesis, and deﬁned levels of c-Myb
protein were shown to correlate with distinct steps of the hemato-
poietic cell development [13]. Gene disruption studies resulted in a
lethal phenotype, conﬁrming the essential role of c-myb in the
generation of myeloid, erythroid and lymphoid lineages [14]. Within
individual cell cycles, the expression ofmyb genesﬂuctuates, with high
level of mRNA and protein detectable in late G1 and S phase [15].
Accordingly, c-myb target genes were shown to be cyclin A, cdc2, DNA
polymerase α, c-kit and c-myc [15]. Microarray-based analysis of global
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themyb-family showed that Myb proteins displayed far more complex
activities than revealed by regular reporter gene assays [16].
Pin1 is a nuclear peptidyl–prolyl isomerase (PPIase) that was
originally identiﬁed in yeast two-hybrid screens as suppressor of
Never In Mitosis A (NIMA), a mitotic kinase of the fungus Aspergillus
nidulans [17]. Structurally, Pin1 consists of an N-terminalWW-domain
and a catalytic C-terminal domain. Binding of theWW-domain of Pin1
to phosphorylated Ser/Thr-Pro motifs of proteins facilitates the cis/
trans rotation about the peptide bond preceding the proline [18].
Pin1 is a nuclear protein that is constantly expressed throughout the
cell cycle [19] in all tissues [20] of the eukaryotes so far examined. Pin1
expression positively correlates with the proliferative status of cells,
the protein being detectable in dividing but not in differentiated cells
[21]. Accordingly, Pin1 is overexpressed in a number of human cancers
[22,23]. The homologous gene in the yeast Saccharomyces cerevisiae,
ESS1, is essential for growth [17,24] and the lethal phenotype resulting
from ESS1 deletion could be rescued by the Drosophila homologue
gene, dodo [25]. Knock-out studies showed that neither the Drosophila
nor the mouse Pin1 is an essential gene [20,25]. No evident defects
were initially observed in Pin1 knock-out mice [20], though later
studies evidenced the presence of multiple proliferative abnormalities
that were strikingly similar to those observed in cyclin D1-null mice
[21]. Studies performed in HeLa cells showed that overexpression of
Pin1 induced arrest at G2, whereas downregulation of Pin1 resulted in
accumulation of mitotic cells [17]. Based on this evidence, an essential
role for Pin1 at the G2/M transition of the cell division cycle was
proposed [17]. Later studies conﬁrmed that Pin1 interacts with and
regulates a number of proteins that exert regulatory functions at
mitosis [19], thus explaining the initial observations. A subset of Pin1
substrates identiﬁed to date consists of transcription factors [26,27].
Of particular relevance was the report on the DNA damage-induced
interaction of Pin1 with p53 [28,29], which led to the conclusion that
Pin1 has other roles in addition to the regulation of mitosis.
In this study we investigated the functional role of c-Myb
phosphorylation at sites that are target of proline-directed kinases.
By means of immunoprecipitation and pull-down studies we
demonstrate that phosphorylation at one such sites (S528) created
the conditions for binding of the peptidyl–prolyl isomerase Pin1. Such
interaction, in turn, led to an elevation of c-Myb transactivation that
was independent of increases in DNA binding.
2. Materials and methods
2.1. Expression vectors, antibodies and chemicals
The expression vector for full-length mouse c-Myb was described before [30].
Expression vectors for human Pin1 (pcDNA3-HA-Pin1 and pGEX-Pin1) were generated
by subcloning Pin1 cDNA from pEVRF1-HA-Pin1.
Point mutations and stop-codons in c-Mybwere introduced using the QuickChange
kit (Stratagene). All constructs were controlled by DNA sequencing.
The antibodies used in this study were as follows: mouse monoclonal to the C-
terminus (clone 1–1, Upstate Biotechnology Inc.) or the N-terminus (clone 5e, a kind gift
of T. Bender) of c-Myb; rabbit polyclonal to the 275–325 regions of c-Myb (05–6, a kind
gift of B. Luescher); rabbit polyclonal to the C-terminus of c-Myb (sc-517, S. Cruz
Biotech); mouse monoclonal to the HA-tag (12CA5, Roche); goat polyclonal to the N-
terminus (sc-7413, S. Cruz Biotech) or the C-terminus (sc-7409, S. Cruz Biotech) of Pin1.
2.2. Cell culture and transient transfections
Human embryo kidney (HEK)-293 cells, HEK-293T cells, and quail QT6 ﬁbroblasts
were maintained in DMEM (Dulbecco's Modiﬁed Eagle Medium) supplemented with
10% (v/v) foetal calf serum (Life Technologies), penicillin (100 U/ml) and streptomycin
(100 μg/ml). Human promyelocytic leukemia HL60 cells were grown in RPMI (GIBCO)
supplemented with 10% (v/v) foetal calf serum (Life Technologies), penicillin (100 U/ml)
and streptomycin (100 μg/ml).
HEK-293 or HEK-293T cells were transiently transfected with either calcium
phosphate or FuGENE-6 (Roche) 24 h after seeding. The amount of expression vectors
used for 3.5 cm tissue culture dishes was: pcDNA3-c-Myb (0.3 μg); pcDNA3-HA-Pin1 or
pcDNA3-Flag-p38MAPK (0.3 μg). Co-transfection of the pCMV-β-galactosidase reporter
gene (0.15 μg) allowed correcting for differences in transfection efﬁciency. Transactiva-tion activity was measured by transfecting cells with 0.15 μg of the Myb-responsive
luciferase reporter gene construct pGL3-3xATk-Luc [30]. Luciferase activity was
determined as described [30].
2.3. Western blot analysis and immunoprecipitation
Cells were lysed in ice-cold lysis buffer (50 mM Tris–HCl, pH 7.5, 120 mM
NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM sodium pyrophosphate, 15 mM
p-nitrophenyl phosphate (pNPP), 0.5 mM sodium orthovanadate, 1 mM benzamidine,
0.1 mM phenylmethylsulfonyl ﬂuoride (PMSF), and 1% Nonidet P-40). Proteins were
resolved on either 10% or 8% SDS-PAGE gels. Retardation of c-Myb mobility was
evidenced by prolonging the electrophoretic separation for 30 min after the front
reached the bottom of the gel. Proteins were transferred to a polyvinylidene diﬂuoride
membrane (PVDF, Millipore) that was probed with the appropriate antibody. Reactive
bands were revealed using the ECL system (GE Healthcare).
Immunoprecipitations were carried out for 3 h or overnight at 4 °C in lysis buffer
using 500–1000 µg of total protein. Antibodies were immobilized on protein G-
Sepharose beads, the resin was washed with 3× 1 ml ice-cold lysis buffer and 1× 1 ml
TNE buffer (50 mM Tris–HCl pH 7.5, 140 mM NaCl, 5 mM EDTA) prior to
electrophoresis.
2.4. Electrophoretic mobility shift assay (EMSA)
The double-stranded probes used in EMSA were obtained by hybridization of the
following single-stranded oligonucleotides:
mim-1A
5'-GCTCTAAAAAACCGTTATAATGTACAGATATCTT-3'
5'-AAGATATCTGTACATTATAACGGTTTTTTAGAG-3'
unspeciﬁc probe
5'-GGAGAGGAAGAAGGACCTGTGTGGGACTCC-3'
5'-GGAGTCCCACACAGGTCCTTCTTCCTCTCC-3'.
Themim-1A double-stranded oligonucleotide (100 ng) was end-labeled using (exo−)-
Klenow polymerase (New England BioLabs) for 1 h at 37 °C in a reaction mixture
containing 10 mM Tris–HCl pH 7.9, 10 mM MgCl2, 50 mM NaCl, 1 mM dithiothreitol and
[α-32P]dCTP in a ﬁnal volume of 40 μl. The labeled oligonucleotide was puriﬁed by
chromatography through a 1 ml Sephadex G25 spin-column and stored at −20 °C.
Nuclear extracts from HEK-293 cells were prepared according to [31]. DNA binding was
performed by incubating nuclear extracts (8 μg) for 45 min on ice in a ﬁnal volume of
20 μl containing the radio-labeled probe (0.5 ng) and 10mM Tris–HCl pH 7.9, 1 mM EDTA,
100 mM NaCl, 10% glycerol, 100 μg/ml bovine serum albumin, 0.5 μg poly(dI:dC) and the
competing speciﬁc or unspeciﬁc oligonucleotides. Samples were loaded on a 6%
polyacrylamide mini-gel and submitted to electrophoresis at 4 °C for 2 h at 100 V. At
the end of the run the gel was immediately dried. Radioactive bands were revealed using
a PhosphorImager model Typhoon 9400 and analyzed using ImageQuant 5.2 software
(GE Healthcare).
Western blot analysis of protein–DNA complexes resolved on EMSA gels was
performed by omitting the gel-drying step and according to the protocol described
above.
2.5. RNA isolation, reverse transcription and quantitative RT-PCR
Total RNA was isolated from transiently transfected 293T cells (7×106) using the
GenElute™ Mammalian Total RNA Kit (Sigma). First-strand cDNA synthesis was
performed with Omniscript Reverse Transcription Kit (Qiagen) according to the
manufacturer's instructions.
Expression of the target gene HEP27 (DHRS2, GeneID: 10202) and of the control
house-keeping gene porphobilinogen deaminase (PBGD, GeneID: 3145) was measured
by qRT–PCR performed with the Roche LightCycler System using the QuantiTect SYBR
Green PCR Kit (Qiagen). The following PCR primers, annealing to cDNA synthesized
from spliced mRNAs but not to genomic DNA, were used: 5'-ATAATCCAGTAG
TGGCGCTG-3' (sense) and 5'-ATTCCCATGAAACACTTTGCTG-3' (antisense) for the
HEP27 transcript and 5'-CAACGGCGGAAGAAAACAG-3' (sense) and 5'-TCTCTCCAATCT-
TAGAGAGTG-3' (antisense) for the PBGD transcript. Relative quantiﬁcation of target
gene was based on the mean Cp (Crossing-point) deviation between different samples
normalized by the mean Cp deviation of the reference gene after efﬁciency correction of
PCR reactions according to Pfafﬂ method [32].
2.6. Mass spectrometric analysis
c-Myb was transiently expressed in HEK-293T cells and immunoprecipitated as
indicated above. The protein band corresponding to c-Myb was excised from the gel,
reduced with 10 mM dithiothreitol (DTT), alkylated with 55 mM iodoacetamide and
cleaved with lysyl-endopeptidase (Wako) in 25 mM ammonium bicarbonate (pH 8.0) at
37 °C overnight [33]. The gel pieces were dried in a Speedvac and peptides were further
digested with endopeptidase Asp-N (Roch) in 25 mM sodium phosphate buffer pH 8 at
37 °C overnight. The extracted peptides were analyzed by capillary liquid chromato-
graphy tandemmass spectrometry (LC–MSMS) using a Magic C18 100 µm×10 cm HPLC
column (Spectronex) connected on-line to a 4000Q Trap (MDS Sciex). The peptides
were loaded for 5 min at a ﬂow of 10 μl/min in buffer A (0.1% formic acid, 2% acetonitrile
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to 10% B (0.1% formic acid, 80% acetonitrile in H2O) (3 min) followed by 10% to 40% B
(75 min) and 40% to 55% (15 min) was delivered with an 1100 Nano-HPLC system
(Agilent) at 300 nl/min. The eluting peptides were ionized by electrospray ionization
and peptide ion mass was measured in the linear ion trap. The detected ions were
automatically selected in Quadrupol 1, fragmented in Quadrupol 2 and the generated
ions were measured in the linear ion trap. Individual MSMS spectra, containing
sequence information for a single peptide, were compared against the mouse subset of
the protein sequence database UNIPROT-12.0 using Mascot software [34].
3. Results
3.1. Pin1 increases c-Myb transactivation activity
Considering that c-Myb contains a number of Ser/Thr-Pro motifs
and that Pin1 controls the function of proteins containing such motifs,
we askedwhether Pin1might regulate c-Myb. To investigate this issue
HEK-293 cells were co-transfected with c-Myb and HA-tagged Pin1.
Transactivation by c-Myb was quantiﬁed using a luciferase reporter
construct containing either three repeats of a Myb-responsive
element (3xATk-Luc) or a similar construct lacking the repeatsFig. 1. Effect of Pin1 on c-Myb transactivation activity. (A) Upper panel: c-Myb transactivatio
binding repeats (−81Tk-Luc) (lanes 1–4) or containing 3 Myb-binding repeats (3ATk-Luc) (la
used to determine transactivation activity. Columns in the upper panel correspond to the lan
or HA-Pin1-A68,69 were examined for transactivation activity on the 3ATk-Luc reporter const
three independent experiments where duplicate measurements were performed. (C) The
quantitative RT-PCR using mRNA obtained from mock-transfected cells or cells transfected(−81Tk-Luc). The data showed that expression of Pin1 led to a net
increase in c-Myb transactivation activity (Fig.1A, 7 vs. 5). The effect of
Pin1 appeared to be speciﬁc since no transactivation could be
observed when the −81Tk-Luc construct was used as read-out
(Fig. 1A, 4 vs. 2). Moreover, co-expression of c-Myb and the
isomerase-deﬁcient mutant Pin1 R68,69NA68,69 did not result in a
signiﬁcant effect on c-Myb activity (Fig. 1B, 6), indicating that Pin1
catalytic activity was required to trigger the observed increase in
transactivation of c-Myb reporter constructs.
To substantiate these ﬁndings and appreciate their biological
implications, we decided to assess the effect of Pin1 on c-Myb-induced
transactivation of endogenous target genes. To this end, we examined
the HEP27 gene, which codes for a member of the alcohol
dehydrogenase/reductase family [35,36] and is controlled by c-Myb
[16]. Using reverse transcribed mRNA as template for quantitative RT-
PCR reactions we observed a mean-fold increase of 6.155 for the
HEP27 transcript in c-Myb tranfected cells with respect to the control
(mock) and of 10.616 in the case of cells transfected with c-Myb and
Pin1 (Fig. 1C and Supplemenatary Fig. 1).n activity determined using luciferase reporter constructs that are either lacking Myb-
nes 5–8). Mock: lanes 1 and 8. Lower panels: Western blot analysis of the cell extracts
es in the lower panel. (B) Extracts of cells transfected with c-Myb and either HA-Pin1-wt
ruct (upper panel) and protein expression (lower panel). Panels A and B show one of the
expression-fold change of c-Myb endogenous target HEP27 gene was examined by
with c-Myb±Pin1.
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c-Myb transactivation activity is of physiological signiﬁcance.
3.2. Pin1 does not increase the extent of c-Myb binding to DNA
Considering the data presented above, we reasoned that the most
obvious mechanism explaining the effect of Pin1 on c-Myb would be
an increase of binding to DNA. To address this question we performed
electrophoretic mobility shift assays (EMSA) using nuclear extracts
derived from cells expressing either c-Myb alone or in combination
with Pin1. A radio-labeled oligonucleotide designed on the mim-1
promoter (−184/−150 region) and containing the MYB-response
element pyAAC(G/T)G was used as speciﬁc probe. The data showed
that the presence of co-expressed Pin1 did not increase binding of c-
Myb to the radio-labeled probe (Fig. 2A, lane 3 vs. 2). Since we
observed one major and one minor labeled band in the EMSA gel, we
decided to assess the speciﬁcity of the interaction between c-Myb and
the mim-1 oligonucleotide. To this end, we transferred proteins from
the EMSA gel to PVDF and probed the membrane with monoclonal
antibody 1–1 (MAb 1–1) to c-Myb. Western blot analysis conﬁrmedFig. 2. Electrophoretic mobility shift assay. (A) DNA binding was examined using nuclear e
incubatedwith the speciﬁc radio-labeled probe (0.5 ng) in the presence or the absence of 10-f
that is selectively competed by the speciﬁc oligonucleotide (lane 4). A representative experim
from the EMSA gel to PVDF and the membrane was probed with MAb 1–1 to c-Myb. The arr
panels A and B.that the major band observed in the EMSA gel contained c-Myb
(Fig. 2B).
Taken together, these data allow concluding that the Pin1-
mediated increase of c-Myb activity was not caused by increased
binding of the transcription factor to DNA.
3.3. Pin1 interacts with c-Myb in a phosphorylation-dependent manner
Considering that phosphorylation at Ser/Thr-Pro motifs creates
docking sites for the peptidyl–prolyl isomerase Pin1 [18] and that
phosphorylation of c-Myb at such sites is well documented [37,38], we
examinedwhether c-Mybwould be capable of binding Pin1. To this end,
HEK-293 cells were co-transfected with c-Myb and HA-tagged Pin1.
Immunoprecipitation of c-Myb with MAb 1–1 and detection of Pin1 by
Western blotting withmonoclonal antibody 12CA5 (MAb 12CA5) to the
HA-tag showed that the two proteins interacted (Fig. 3A, lane 4). The
reciprocal approach, where Pin1 was immunoprecipitated with MAb
12CA5and c-MybwasdetectedwithMAb1–1, conﬁrmed the interaction
(Fig. 3B, lane 2). Co-expression of c-Myb and the Pin1 R68,69NA68,69
double mutant, which carries mutations at sites responsible forxtracts (8 μg) derived from HEK-293 cells transfected with c-Myb±Pin1. Extracts were
old excess unlabeled speciﬁc or unspeciﬁc oligonucleotide. The arrow indicates the band
ent of ﬁve independent assays is shown. (B) Proteins–DNA complexes were transferred
ow indicates the position of c-Myb. (C) Western blot analysis of nuclear extracts used in
Fig. 3. c-Myb interacts with Pin1 in a phosphorylation-dependent manner. (A) HEK-293 cells were mock transfected or transfected with c-Myb-wt or c-Myb-A528 in the presence or the
absence of HA-Pin1. Immunoprecipitation of c-Myb was carried out with MAb 1–1 and proteins were detected with MAb 1–1 (to c-Myb) or MAb 12CA5 (to HA-Pin1). WCE = whole cell
extracts. (B) Reciprocal immunoprecipitation using MAb 12CA5 (to HA-Pin1). (C) HEK-293 cells were co-transfected with c-Myb-wt and either HA-Pin1-wt or HA-Pin1-A68,69.
Immunoprecipitationwas carried outwithMAb 1–1.WCE =whole cell extracts. (D) Immunoprecipitation of HA-Pin1 fromHEK-293 cells that weremock transfected (lane 4) or tranfected
with c-Myb-wt (lane 5), c-Myb1–510 (lane 6) or c-Myb1–550 (lane 7) deletion mutants along with HA-Pin1. c-Myb isoforms were detected with monoclonal antibody 5e to the N-terminus
of the protein. WCE = whole cell extracts. (E) In vitro interaction of Pin1 and c-Myb. Pull-down from extracts of QT6 cells ectopically expressing c-Mybwas performed using puriﬁed GST-
tagged Pin1. Western blot analysis with MAb 1–1 shows proteins interacting with GST (lane 2) or GST-Pin1 (lane 3). The input (2.5%) is shown in lane 1. (F) Immunoprecipitation of
endogenous c-Myb from HL60 cells (lane 3). Controls for the migration of endogenous c-Myb and Pin1 proteins (lane 1) and the antibody (lane 2) are shown.
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[39], showed that the two proteins interacted (Fig. 3C, lane 7).
One of the ﬁrst sites of phosphorylation identiﬁed in c-Myb, S528,
displays the Ser-Pro motif, is targeted by MAPK [37] and is located in
the C-terminal regulatory domain of the protein. We asked whether
mutation of S528 to alanine would affect the interaction between c-
Myb and Pin1. Immunoprecipitation experiments indicated that the c-
Myb-A528 mutant was unable to interact with Pin1 (Fig. 3A, lane 5 and
Fig. 3B, lane 3), pointing to a role for phosphorylation at this site. Since
MAPK-dependent phosphorylation events are transient in nature, we
decided to examine the status of S528 phosphorylation in vivo. To this
end, c-Myb was immunoprecipitated from transfected 293T cells in
exponential growth phase and the protein was examined by mass
spectrometry (MS). LC–MS analysis identiﬁed one major phospho-
peptide displaying the sequence IKQEVESPTEK. The measured mass of
1366.59 was in good agreement with the theoretical mass for this
peptide containing a single phosphate (1366.64) (Fig. 4). Loss of
phosphoric acid from the doubly-charged precursor ion (684.3) as
well as from the y5- to y10-ions could be detected. Additionally,
detection of phosphorylated y7- and y8-ions conﬁrmed that thepeptide was phosphorylated. Finally, the mass of the y4-fragment
(474.1) indicated lack of phosphate groups on the last C-terminal
residues of the peptide, allowing to deﬁnitely assign phosphorylation
to S528 (Fig. 4).
In addition to the c-Myb-A528 pointmutant,weexamined thec-Myb/
Pin1 interaction using two C-terminal deletion mutants of c-Myb that
were either lacking (c-Myb1–510) or comprising (c-Myb1–550) the EVES-
domain inwhich S528 is located. Although the c-Myb1–510migrates close
to the IgG(H) band,we couldnot detect anyco-precipitationwith Pin1 in
several independent experiments. On the contrary, the c-Myb1–550
mutant was able to interact with Pin1 (Fig. 3D).
To further substantiate the evidence on the Pin1/c-Myb interac-
tion, we performed pull-down assays with GST-tagged Pin1 using
extracts of QT6 ﬁbroblasts expressing c-Myb. The data showed that
GST-Pin1 was capable of interacting with c-Myb (Fig. 3E, lane 3). Most
importantly, interaction of the resident proteins c-Myb and Pin1 was
readily detectable upon precipitation of c-Myb from extracts obtained
from the promyelocytic leukemia cell line HL60 (Fig. 3F). This ruled
out the possibility that the observed c-Myb/Pin1 interaction could be
an artifact of overexpression studies.
Fig. 4. CID tandem mass spectrum of phospho-peptide IKQEVESPTEK. The y- and b-fragments detected are indicated in the sequence. Fragments showing loss of H3PO4 are marked
with an asterisk. The site of phosphorylation (pS) is indicated in the sequence of the peptide.
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in a phosphorylation-dependent manner and that the site responsible
for such interaction is S528.
3.4. Functional analysis of c-Myb mutants
Based on the evidence that phosphorylation at S528 in c-Mybwas a
relevant mediator of the interaction with Pin1, we examined the
impact of the S528NAmutation on transactivation activity. In addition,
we systematically examined point mutants of Ser/Thr-Pro sites in c-
Myb (Fig. 5A). Among the mutants examined, A354 and to a lesser
extent of A370, A422 and A464 displayed higher basal transactivation
activity thanwild-type c-Myb and a proportionally lower induction by
Pin1 (Fig. 5B). Remarkably however, the only mutant displaying little,
if any, induction of transactivation activity by Pin1 was A528 (Fig. 5B),
thus conﬁrming the data obtained in the protein interaction studies.
4. Discussion
Evidence for the role playedbymyb in cell proliferationwasprovided
by the ﬁnding that the v-myb oncogene causes avian leukemia [2,3] and
that theprogenitor c-mybgene controls certain aspects ofhematopoiesis
[14]. Detection of c-myb expression in tissues other than the hemato-
poietic compartment [10,11] as well as recent evidence showing the
involvement of c-myb in the development of human cancer [5]
conﬁrmed and extended the role initially proposed for c-myb.
Our study was prompted by the observation that phosphorylation
is among the post-translational modiﬁcations that control c-Myb
protein stability and transactivation activity. Hyperphosphorylation of
c-Myb was detected during mitosis and was postulated to facilitate
release of the protein from chromatin during chromosome condensa-
tion [40]. Two neighboring residues at the N-terminus of the protein,
S11 and S12, were described as CK2 targets [41–43], whereas S8 and S116
were reported as in vitro sites for protein kinase A (PKA) [44,45]. S528
was described as in vitro and in vivo target of the mitogen activated
protein kinase (MAPK) [37]. Although point mutation of this site toalanine was reported to increase c-Myb-dependent transactivation of
the CD34 promoter, thus pointing to a negative role of phosphoryla-
tion at S528, this seemed to be a peculiarity of the CD34 promoter, since
this effect could not be reproduced with any promoter containing
Myb-responsive elements [46,47]. Finally, p38MAPKδ-dependent
phosphorylation at Thr354, Thr486, Ser556 and Thr572 was shown to
control c-Myb protein stability [48].
In the present study we decided to address the functional
consequences of c-Myb phosphorylation at sites for proline-directed
kinases like MAPK. Based on the reasoning that phosphorylation at
Ser-Thr/Pro sites creates the conditions for the formation of multi-
meric signaling complexes [49] involving WW-domain [50] or Polo-
Box domain-containing proteins [51], we examined the possibility
that c-Myb interacts with Pin1. Pin1 is an isomerase that facilitates the
cis–trans interconversion of the peptide bond preceding a proline [18]
and in such manner regulates protein functions [52].
Our data show that Pin1 was able to positively affect c-Myb
transactivation activity in a manner that was strictly dependent on the
presence of an intact catalytic center in Pin1. This effect appeared to be
speciﬁc, since a reporter construct missing Myb-responsive elements
could not be transactivated, thus ruling out an effect of Pin1 on the
general transcriptional machinery. More importantly, we found that
expression of an established endogenous c-Myb target, the HEP27
gene, was increased in cells ectopically expressing c-Myb and Pin1 as
compared to cells expressing c-Myb alone. This indicated that the
positive effect of Pin1 on c-Myb activity is of biological signiﬁcance.
DNA-binding studies revealed that Pin1 was not able to increase
the afﬁnity of c-Myb for its response element in DNA, indicating that
the effect of Pin1 could not be merely ascribed to increased
recruitment of the factor to DNA.
In order to distinguish whether the Pin1-dependent increase of
c-Myb activity was the result of a direct effect on c-Myb or an indirect
effect through proteins that interact with c-Myb and are required as
co-activators of transcription, we carried out protein interaction
studies. Immunoprecipitation experiments that we performed in
model cell lines where c-Myb and Pin1 were ectopically expressed
Fig. 5. Effect of Pin1 on the transactivation activity of c-Myb phosphorylation mutants. (A) Schematic representation of c-Myb. The position of potential sites of phosphorylation
fulﬁlling the requirement for recognition by proline-directed kinases is indicated. DBD = DNA-binding domain; TAD = transactivation domain; CRD = C-terminal regulatory domain;
the position of the EVES-motif is indicated. (B) Transactivation activity of c-Myb Ala mutants was determined in the presence or the absence of co-expressed Pin1. (C) Upper panels:
Western blot analysis of the cell extracts used to determine the transactivation activity shown in B. Lower panels: Ponceau-red (PR) staining was used to ensure equal loading. Panels
B and C show a representative of three independent experiments in which measurements were performed in duplicate.
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Myb and Pin1 interacted. Pull-down studies performed on extracts of
QT6 cells expressing c-Myb and using GST-tagged Pin1 as bait
conﬁrmed this interaction. Furthermore, mutation of Pin1 at sites
that impair enzymatic activity but that leave unaffected the ability to
recognize and bind phosphorylated Ser-Thr/Pro motifs [18], did not
inﬂuence the c-Myb/Pin1 interaction. However, in this case the
interactionwas not productive, indicating that a Pin1-induced change
of conformation was likely necessary to trigger the increase of c-Myb
activity. As a whole, these data indicated that the interaction between
c-Myb and Pin1 is direct.
Characterization of the Pin1/c-Myb binding at the molecular level
was conducted using c-Myb mutants of Ser/Thr-Pro sites. The data
showed that interaction of c-Myb with Pin1 was abolished upon
mutation of S528 to alanine. Mass spectrometric analysis of c-Myb that
was immunoprecipitated from cells in exponential growth phase,
revealed that c-Myb was phosphorylated at S528. Although the
stoichiometry of phosphorylation at this site could not be assessed
from the MS data, the results indicate that the kinase responsible for
phosphorylation of S528 was active in exponentially growing cells.
Indeed, we have recently obtained evidence that, whereas p38MAPK
and JNK are inactive under these conditions, ERK1 and ERK2 are active[48]. This is not surprising, considering that the MAPK family
members ERK1 and ERK2 play important roles throughout the cell
cycle, as for instance inmitosis [53,54] and in the regulation of G1 [55].
In agreement with the protein interaction data, systematic analysis of
c-Myb phosphorylation site mutants showed that the S528NA was the
only mutant displaying a signiﬁcantly reduced induction by Pin1.
S528 is located in the conserved EVES-motif, which is part of c-Myb
negative regulatory domain [56]. The EVES-motif was shown to
interact with c-Myb DNA-binding domain and, through competition
with c-Myb activators containing the same EVES-motif, inhibit
transactivation activity [57]. Considering this, an alternative explana-
tion for the lack of Pin1 binding to c-Myb-A528 and the lack of
induction of transactivation for this mutant could be that mutation
of S528 to alanine strengthens intramolecular interaction between the
N- and the C-terminal domains of c-Myb. There are, however, two
arguments against this possibility: (i) if afﬁnity of the two c-Myb ends
would be increased in the A528 setting, then the basal transactivation
activity of such mutant should be decreased compared to wild-type c-
Myb. This was not the case in any of the experiments that we have
conducted. And (ii) the in vitro interaction between c-Myb DBD and
EVES-constructs that were expressed in bacteria, and were therefore
unphosphorylated, could not be demonstrated [57]. This led the
1128 E. Pani et al. / Biochimica et Biophysica Acta 1783 (2008) 1121–1128authors to suggest that phosphorylation of the serine in the EVES-
motif may be required for this intramolecular interaction to occur [57].
Nonetheless, we decided to assess this issue by generating two c-Myb
deletion mutants that either contained or lacked the EVES-motif. Co-
immunoprecipitation experiments showed that mutant c-Myb1–550
was able to interact with Pin1, whereas c-Myb1–510 was not.
An alternative explanation for the effect observed upon mutating
S528 could be that a point mutation in a highly conserved domain
might result in unexpected effects on the conformation of the c-Myb
protein. Although this possibility cannot be completely excluded
without detailed structural analysis, it seems unlikely, since three
single point mutations that we introduced in another highly
conserved c-Myb domain (S458–P465), as well as their combination
in a triple mutant, had no effect on stability [48] or activity of c-Myb
(Fig. 5 and data not shown).
c-Myb has been previously shown to interact with the peptidyl–
prolyl isomerase Cyp40, which is able to inhibit c-Myb function
through inactivation of DNA binding [58]. The authors provided
evidence that cyclosporine could selectively block Cyp40-mediated
inhibition of DNA binding, and for this to occur an intact C-terminal
domain of c-Myb was necessary [58]. The site of interaction of Cyp40-
TPR repeats with c-Myb was mapped in the DNA-binding domain.
Contrary to Cyp40, in the case of Pin1 the site of interaction appears to
be S528 of the EVES-motif and phosphorylation of this site appears to
be necessary. In addition, the interaction with Pin1 promotes an
increase of c-Myb activity.
The results presented here led us in speculating that isomerization
of the peptidyl–prolyl bond at pS528-Pro529 in c-Myb is very likely a
necessary requirement for the Pin1-induced increase in transactiva-
tion activity. One could envisage that Pin1-driven conformational
changes of c-Myb structure may result in either the relief of an
inhibitory factor/function from c-Myb transactivation domain or
facilitate interaction of c-Myb with co-activators of transcription [59].
Future experiments in our laboratory will aim at co-crystallizing c-
Myb and Pin1 to gain information on the effect of the latter on c-Myb
conformation and at assessing how this may reﬂect on the set of
protein interactions made c-Myb.
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